Embedding Strategic and Operational Excellence: A Clear Strategic Focus

A well understood and clearly communicated strategic focus is the first and most important step towards strategic and operational excellence. Each team in the organisation must be aligned with its priority activities and understand how it delivers value to stakeholders and patients. Download our one-pager via the button above.

Pharma/Biotech R&D Effectiveness: What it Takes – Exclusive Workshop

On Thursday 22nd September, Novasecta and WittKieffer Executive Search will be co-hosting a face-to-face workshop to discuss what it takes to be effective in the interaction between early commercial strategy and R&D. During this workshop, John Rountree, Managing Partner of Novasecta, will facilitate a Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, […]

How European MidPharmas have grown profits (MedNous)

Europe is home to 85 mid-sized pharmaceutical companies (MidPharmas) that invest in developing and commercialising pharmaceutical products. Many of these companies have achieved impressive, upward-trending earnings before interest and tax (EBIT) margins in the last five years. The median EBIT margin of MidPharma is now comparable to that of the largest pharma companies and many […]

How European MidPharmas have grown profits

Europe is home to 85 mid-sized pharmaceutical companies (MidPharmas) that invest in developing and commercialising pharmaceutical products. Many of these companies have achieved impressive, upward-trending earnings before interest and tax (EBIT) margins in the last five years. The median EBIT margin of MidPharma is now comparable to that of the largest pharma companies and many […]

Five Imperatives For Strategic And Operational Excellence

As technological advances and competition in the pharmaceutical ecosystem accelerate, it is vital for companies to stay at the cutting edge. The leading pharmaceutical companies focus, move fast and move together. They embrace strategic and operational excellence. Why is strategic and operational excellence important? Pharmaceutical and biotech companies must optimise the effectiveness of the multiple […]

Reimagine Pharma’s Commercial Model

Digitisation has already impacted, and will continue to transform, how pharma’s commercial teams interact with healthcare professionals, engage with patients, and evolve their salesforce. The COVID-19 pandemic has accelerated the previously incremental steps of digitisation for commercial teams. During lockdown, it became much more difficult for salespeople to access physicians in person – this has […]

Reimagine Medical Affairs

Medical Affairs has traditionally been an under-represented function in pharmaceutical decision-making. Yet more recently leading pharmaceutical companies have started to make much better use of Medical Affairs’ ability to understand and amplify the patient voice, resulting in higher quality R&D and Commercial decision-making. In this webinar, Andrew Bell of Novasecta was joined by Jill Massey […]

Enrich the R&D pipeline

Challenge A newly established R&D therapeutic area team was tasked with creating attractive commercial opportunities to drive future growth beyond a Pharma company’s core therapeutic area. The new team, which integrated two previously separate teams, required a clear focus to align on how to maximise value creation from its combined portfolio and enrich its future […]

Enable successful commercial expansion

Challenge A Pharma company with an attractive late-stage pipeline sought to strengthen its commercial footprint in an important region for one of its therapeutic areas. Key stakeholders were not aligned on whether to self-build, acquire or partner in order to best create value, as there was insufficient insight into how feasible each option was. Solution […]

Deliver a new corporate direction

Challenge A specialty Pharma company needed to diversify given a narrow therapeutic area focus, a commercial footprint overly reliant on a single market, and a generic threat to its lead asset. An incremental business case mindset was leading the company to over-invest in short-term growth at the expense of strategically de-risking the company for shareholders. […]